Sorrento's TNK Therapeutics Subsidiary Acquires Multiple Clinical Stage CAR-T Immunotherapy Programs
SAN DIEGO, Aug. 10, 2015 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (Sorrento) announced today that its wholly-owned subsidiary, TNK Therapeutics, Inc., has acquired multiple ...
The adoptive transfer of CD19-specific chimeric antigen receptor engineered T cells (CAR T cells) resulted in encouraging clinical trials in indolent B-cell malignancies. However, they also show the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results